Roche Cancer Drug (Tecentriq a PD-1 inhibitor) Rises To Challenge Merck, Bristol-Myers | Forbes https://t.co/QJ8s6jgqCt
1:20pm November 20th 2017 via Hootsuite
Announcing the winner of this year’s ‘Dance Your Ph.D.’ contest | Science | AAAS https://t.co/wwTvf60fhI
12:15pm November 20th 2017 via Hootsuite
Gene Editors, Cancer Killers And Smartphone Apps: The 2018 30 Under 30 In Healthcare | Forbes https://t.co/3vo08ZzdQe
9:50am November 20th 2017 via Hootsuite
Three tech breakthroughs that will help transform the world - The Washington Post https://t.co/EK5C2bPwAt
8:05am November 20th 2017 via Hootsuite
RT @adriaexists: That's right. Funny scientists taking the world by storm. #intelligentpeopleliketolaugh https://t.co/RjES0WjjfM
7:15am November 20th 2017 via Hootsuite
Computer Resources Collection | Cancer Research https://t.co/pe67xGzyCc
6:55am November 20th 2017 via Hootsuite
November Bioinformatics and Data Science Papers · seandavi(s12) https://t.co/1OVRqh39xh
8:55pm November 19th 2017 via Hootsuite
The Complete Moral Bankruptcy of Manipulating Human Psychology To Turn Users Into Addicts | Medium https://t.co/PoV5qNSa0Z
7:43pm November 19th 2017 via Hootsuite
RT @ariv2013: Great Work @Robyn_Temple @TBurkePhD @deepualexmd @ChrisColdren @Sinchita_Roy @PancPathologist @gizbab… https://t.co/DVELUtJyKT
2:50pm November 19th 2017 via Hootsuite
@Massgenomics I enjoyed your #AMP2017 presentation very much Dan! All the best.
2:35pm November 19th 2017 via Hootsuite in reply to Massgenomics
RT @ritikamihani: 11.16.17! Met @DaleYuzuki and heard a talk by Dan Koboldt #fangirling #AMP2017
2:34pm November 19th 2017 via Hootsuite
Ancient data, modern math and the hunt for 11 lost cities of the Bronze Age - Washington Post https://t.co/XLmVQmZVxd
1:45pm November 19th 2017 via Hootsuite
How a DNA revolution has decoded the origins of our humanity - The Guardian https://t.co/0b4pFSZ0yJ
12:45pm November 19th 2017 via Hootsuite
RT @Rafal_M: (Unsurprisingly) early career researchers want #openscience - and speak up about it: https://t.co/Uv52zZjmfr
11:50am November 19th 2017 via Hootsuite
RT @DrChromo: This looks really interesting "Statistical and integrative system-level analysis of DNA methylation d… https://t.co/KbPr5vo5dW
9:50am November 19th 2017 via Hootsuite
The Inova Personalized Health Accelerator is ready to launch - Technical.ly DC https://t.co/QY7Tzaoyzg
8:55am November 19th 2017 via Hootsuite
@mzkhalil Not sure what you mean by 'open access tweets', as they are by definition available (to countries that ha… https://t.co/ozxgsjTAzc
7:55am November 19th 2017 via Hootsuite in reply to mzkhalil
ICYMI: Pillar Biosciences at Association for Molecular Pathology #AMP2017 https://t.co/CS1fFbP4kz
7:39am November 19th 2017 via Hootsuite
New post: Pillar Biosciences at Association for Molecular Pathology #AMP2017 https://t.co/CS1fFbP4kz
7:05pm November 18th 2017 via WP to TWTR on Yuzuki.org
Q: Same coverage depth for WGS, WES? Jennings: "No." The allele burden is different. Binomials illus - how to sep FP from TP #AMP2017
1:54pm November 18th 2017 via Hootsuite
Q: 250x min read count; but base and map quality? Jennings: FP/FN was statistical model on 1% error. #AMP2017
1:50pm November 18th 2017 via Hootsuite
Jennings: New guideline rec'd an 'error-based approach'. #AMP2017
1:49pm November 18th 2017 via Hootsuite
Jennings: Rec'd appropriate design mods or controls when potential errors remain high. FLT3-ITD - will you have 59 samples? #AMP2017
1:48pm November 18th 2017 via Hootsuite
Jennings: CI useful but for that next sample, tolerance interval impt. Population distribution may be different shapes #AMP2017
1:43pm November 18th 2017 via Hootsuite
Jennings: 20 samples is good for est of mean; ave read depth 95% CI 253 to 301x read depth. Tolerance interval introduced #AMP2017
Jennings: '17 J Mol Diag paper https://t.co/Nl9RcmfiqI AMP/CAP guidelines for validation of oncology panels #AMP2017
1:41pm November 18th 2017 via Hootsuite
Lawrence Jennings (Childrens Hosp Chicago IL) AMP/Cap guidelines for validation of NGS-based oncology panels #AMP2017
1:37pm November 18th 2017 via Hootsuite
Li: Went through three detailed case studies in Dx. Last was a novel EWSR1-CREB3L3 fusion, ended up w/radical mandible resection #AMP2017
1:35pm November 18th 2017 via Hootsuite
Li: change of gears: CHOP NGS Panel description: large for solid, heme, fusion and hereditary. All coding flanking 10bp#AMP2017
1:27pm November 18th 2017 via Hootsuite
Li: Other rec's: clear desc of clin sig; clear desc of confirmation methods. Ref J Mol Diagn '17 https://t.co/Noyq5Y9Fzv #AMP2017
1:26pm November 18th 2017 via Hootsuite
Li: Var nomenclature: Gene name; Transcript ID accession and ver number; nucleotide change; aa change; VAF; coord's… https://t.co/hbf4qTb76H
1:24pm November 18th 2017 via Hootsuite
Li: Shows a few examples of older / newer classification. Recommend 4-tier reporting, only 1-3 to physician. #AMP2017
1:22pm November 18th 2017 via Hootsuite
Li: Germline in tumor testing: Consider gene char - tumor supp or oncogene; pt information, family history etc #AMP2017
1:20pm November 18th 2017 via Hootsuite
Li: Tier IV benign / likely benign. Find germline vars in tumor testing: var freq usu 50% for germline. But CNVs mu… https://t.co/F8t8Spm5U1
1:19pm November 18th 2017 via Hootsuite
Li: Ex of Tier III, vars of unk sig, showed on dbSNP entry, low freq, controversial via SIFT and other tools #AMP2017
1:16pm November 18th 2017 via Hootsuite
Li: Tier II: fusion in Ph-like ALL, GENEA1-JAK2. No drug, in pediatric case, no guidelines at present. db's don't apply. #AMP2017
1:15pm November 18th 2017 via Hootsuite
Li: (Tier III/IV have insufficient evidence, a matter of degree.) Tier I examples: EGFR exon 14 18bp inframe del, shows chart #AMP2017
1:13pm November 18th 2017 via Hootsuite
Li: Tier II evidence is var's of potential clin significance. Level C/D. #AMP2017
1:11pm November 18th 2017 via Hootsuite
Li: Evidence-based char: Tier I vars have strong clinical significance, includes Level A and Level B evidence. #AMP2017
1:10pm November 18th 2017 via Hootsuite
Li: Dx/Prog for Lvl D: TP53 common muts, deletion of CDKN2A also. #AMP2017
1:09pm November 18th 2017 via Hootsuite
Li: Lvl D: Rx plausible preclin data derived from cell lines (in vitro) and animal models. Early Ph1 for safety. #AMP2017
1:08pm November 18th 2017 via Hootsuite
Li: Lvl C MDS-RS + SF3B1 mut good prognosis. #AMP2017
1:07pm November 18th 2017 via Hootsuite
Li: Lvl C Rx: Ph-like ALL: P2RY8-CRLF2 activates JAK-STAT, clin trial using JAKi. Lvl C Dx: spliceosome mutations #AMP2017
Li: Pilocytic Astrocytoma - KIAA1549-BRAF -> good prognosis, level B evidence for prongnosis #AMP2017
1:05pm November 18th 2017 via Hootsuite
Li: Lvl B Dx: Cutaneous mastocytosis, others types ruled out. KIT D816V found in bone marrow of ~100% CM pts. #AMP2017
1:04pm November 18th 2017 via Hootsuite
Li: Level B vars: for Rx, very strong evidence, not FDA-approved. Hairy Cell Leuk: BRAF V600E ~100% response to vemurafenib #AMP2017
1:03pm November 18th 2017 via Hootsuite
Li: Leval A Dx: prof guidelines. Level A prognosis: also prof guidelines. In AML, FLT3-ITD -> poor prognosis #AMP2017
1:01pm November 18th 2017 via Hootsuite
Li: Level A Rx: FDA-approved biomarker for spec Rx; or predict response. Ex ALK mut predicts resistance #AMP2017
12:59pm November 18th 2017 via Hootsuite
Li: Grouped evidence to 4 levels: A-D, clinical and/or expt'l evidence. Therapeutics, diagnosis, prognosis. #AMP2017
12:58pm November 18th 2017 via Hootsuite
Li: Biomarker can alter fn of gene, can serve to include to trials, influence prognosis, est Dx, may warrant surveillance #AMP2017
12:57pm November 18th 2017 via Hootsuite
